PTGS2 and neoplasm: PPARγ agonists reduce mammary carcinogenesis [17–19], which correlates with induction of PTEN [20, 21] and BRCA1 [22] tumor suppressor activity, as well as reduction of inflammation via the Cox2/Ptgs2 pathway [23].